Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit

Memarzadeh, Farnaz; Varma, Rohit; Lin, Le-Tien; Parikh, Jignesh; Dustin, Laurie; Alcaraz, Ana; Eliott, Dean

doi:10.1167/iovs.08-2441

Cited by 108 publications

(87 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 The subconjunctival injection of bevacizumab was found to be associated with improvements in trabeculectomy bleb survival in glaucoma, which suggests that bevacizumab may be a useful agent for improving the success rate and limiting scar tissue formation after trabeculectomy. 22 This study aimed to evaluate the additive effect of bevacizumab to MMC-augmented trabeculectomy in recurrent cases of childhood glaucoma concerning its efficacy and complications. Our results revealed that the mean age was 2.16 ± 1.5 (range 7 months to 4.1 years); this explains the failure of the primary surgery in these children because a younger age results in a lower success rate.…”

Section: Discussionmentioning

confidence: 99%

Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma

Mahdy

Al-Mosallamy

Al-Aswad

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To evaluate the efficacy and safety of combined bevacizumab-mitomycin c (MMC) in recurrent cases of pediatric glaucoma. Methods A prospective non-masked controlled study that included bilateral cases of 12 patients (24 eyes) with recurrent (had previous glaucoma surgery before) pediatric glaucoma. One eye in each patient (12 eyes) was assigned to trabeculectomy operation with combined application of MMC (0.4 mg/ml for 3 min) under and around the scleral flap before trabeculectomy and bevacizumab (avastin) (2.5 mg in 0.2 ml) injected subconjunctivally around the bleb after completing the surgery (group I). The other eye of each patient (12 eyes) was assigned to trabeculectomy operation with application of MMC (0.4 mg/ml for 3 min) only (group II). The mean follow-up period was 13 ± 1 months.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma

Mahdy

Al-Mosallamy

Al-Aswad

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…В ходе иссле-дования наблюдалось выраженное влияние инги-битора VEGF на морфологические характеристики и функционирование фильтрационной подушки. Результаты гистологических и иммуногистохими-ческих методов подтвердили существенное сни-жение выраженности рубцовых и фиброзных из-менений под влиянием анти-VEGF [50]. В 2010 г. сходное экспериментальное исследование было проведено A.…”

Section: применение ингибиторов Vegf после фистулизирующих антиглаукоunclassified

VEGF inhibitors in glaucoma surgery

Mamikonyan¹,

Petrov²,

Сафонова³

2016

Ophthalmology Reports

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a signaling protein, that controls vasculogenesis, angiogenesis, vascular support and stimulates permeability of small blood vessels. The following isoforms are presently known: VEGF-A, VEGF-B, VEGF-C, VEGF-В and PGF. VEGF-A, that regulates neoangiogenesis and fibroblast formation, is thought to play the most important role in human organism. Increased expression of VEGF may lead to development and aggravation of pathological conditions including oncology. The article presents a review of preclinical and clinical studies of the main VEGF-inhibitors - bevacizumab and ranibizumab, as well as a brief account on other existing medications of this group. It describes ophthalmological indications for the use of antiangiogenetic agents, as well as the ways of their possible off-label use. The review presents investigations of intravitreal and intracameral injections of VEGF-inhibitors in patients with retinal, chorioidal, iris, and anterior chamber angle neovascularization. It gives examples of successful anti-VEGF use before Ahmed glaucoma valve drainage device implantation and in cases of neovascular glaucoma, induced by radiation therapy for intraocular tumors. Tenon’s capsule’s fibroblasts take part in the process of postoperative wound healing and scarring. According to the latest research, this process could be modulated by angiogenesis inhibitors. This review also recounts the use of anti-angiogenic agents to inhibit postoperative fibroblast proliferation, when used as monotherapy, or as an adjuvant to mitomycin С or 5-fluorouracil. It reviews the research on VEGF-inibitors use in combination with postoperative needling.

show abstract

“…In animal models of trabeculectomy, adjunctive bevacizumab, a monoclonal antibody to VEGF-A, was associated with inhibition of Tenon's fibroblast proliferation, decreased collagen deposition and decreased fibroblast differentiation into myofibroblasts, leading to more favourable bleb morphology and longer bleb survival. [5][6][7][8] Given these encouraging animal model results, we designed a pilot clinical trial using ranibizumab, a Fab fragment of a recombinant humanized immunoglobulin G1k isotype murine monoclonal antibody to VEGF-A. The purpose of our small randomized, controlled trial was to determine whether or not intravitreal ranibizumab therapy before and after Ahmed tube insertion for open-angle glaucoma (OAG) could be a safe method to prevent scar tissue formation and achieve better intraocular pressure (IOP) control.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open‐angle glaucoma: a pilot study

Desai

Singh

Lin

2012

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit

Abstract: Postoperative subconjunctival injection of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model. Bevacizumab may be a useful agent for improving success and limiting scar tissue formation after trabeculectomy.

Cited by 108 publications

References 21 publications

Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma

Evaluation the adjunctive use of combined bevacizumab and mitomycinc to trabeculectomy in management of recurrent pediatric glaucoma

VEGF inhibitors in glaucoma surgery

Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open‐angle glaucoma: a pilot study

Contact Info

Product

Resources

About